Deerfield Management Co buys $38,057,525 stake in Global Blood Therapeutics Inc (GBT)

Global Blood Therapeutics Inc (GBT) : Deerfield Management Co scooped up 540,017 additional shares in Global Blood Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,733,828 shares of Global Blood Therapeutics Inc which is valued at $38,057,525.Global Blood Therapeutics Inc makes up approximately 1.66% of Deerfield Management Co’s portfolio.

Other Hedge Funds, Including , Partner Fund Management boosted its stake in GBT in the latest quarter, The investment management firm added 38,999 additional shares and now holds a total of 742,986 shares of Global Blood Therapeutics Inc which is valued at $16,308,543. Global Blood Therapeutics Inc makes up approx 0.56% of Partner Fund Management’s portfolio.Spark Investment Management boosted its stake in GBT in the latest quarter, The investment management firm added 63,400 additional shares and now holds a total of 154,000 shares of Global Blood Therapeutics Inc which is valued at $3,380,300. Global Blood Therapeutics Inc makes up approx 0.29% of Spark Investment Management’s portfolio.Blackrock Investment Management boosted its stake in GBT in the latest quarter, The investment management firm added 46,486 additional shares and now holds a total of 70,327 shares of Global Blood Therapeutics Inc which is valued at $1,543,678. New York State Common Retirement Fund added GBT to its portfolio by purchasing 7,200 company shares during the most recent quarter which is valued at $316,080. Lmr Partners Llp added GBT to its portfolio by purchasing 63,531 company shares during the most recent quarter which is valued at $1,135,934. Global Blood Therapeutics Inc makes up approx 0.17% of Lmr Partners Llp’s portfolio.

On the company’s financial health, Global Blood Therapeutics Inc reported $-0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 10, 2016. Analyst had a consensus of $-0.63.During the same quarter in the previous year, the company posted $-4.84 EPS.

Global Blood Therapeutics Inc. is a biopharmaceutical company that engages in discovering developing and commercializing therapeutics to treat blood-based disorders. The Company is engaged in developing initial product candidate GBT440 oral prophylactic therapy for sickle cell disease (SCD). The Company offers randomized placebo-controlled double-blind single and multiple ascending dose Phase 1/2 clinical trial of GBT440 in healthy subjects and patients with SCD. It is also developing hemoglobin modifiers for pulmonary disorders such as acute respiratory distress syndrome in which increased oxygen delivery is needed. The Company through its GBT440 or analog also focuses on chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary angioedema (HAE) which is in pre-clinical trials. In addition the Company develops TBD an oral kallikrein inhibitor which are in Phase 1/2 clinical trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *